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Abstract
Introduction Randomized trials indicate that adjuvant
radiotherapy plus tamoxifen decrease the five-year risk of
recurrence among ductal carcinoma in situ patients treated with
breast-conserving surgery from about 20% to 8%. The aims of
this study were to examine the use and impact of these therapies
on risk of recurrence among ductal carcinoma in situ patients
diagnosed and treated in the community setting.
Methods We identified 2,995 patients diagnosed with ductal
carcinoma in situ between 1990 and 2001 and treated with
breast-conserving surgery at three large health plans. Medical
charts were reviewed to confirm diagnosis and treatment and to
obtain information on subsequent breast cancers. On a subset
of patients, slides from the index ductal carcinoma in situ were
reviewed for histopathologic features. Cumulative incidence
curves were generated and Cox regression was used to
examine changes in five-year risk of recurrence across diagnosis
years, with and without adjusting for trends in use of adjuvant
therapies.
Results Use of radiotherapy increased from 25.8% in 1990-
1991 to 61.3% in 2000-2001; tamoxifen increased from 2.3%
to 34.4%. A total of 245 patients had a local recurrence within
five years of their index ductal carcinoma in situ. The five-year
risk of any local recurrence decreased from 14.3% (95%
confidence interval 9.8 to 18.7) for patients diagnosed in 1990-
1991 to 7.7% (95% confidence interval 5.5 to 9.9) for patients
diagnosed in 1998-1999; invasive recurrence decreased from
7.0% (95% confidence interval 3.8 to 10.3) to 3.1% (95%
confidence interval 1.7 to 4.6). In Cox models, the association
between diagnosis year and risk of recurrence was modestly
attenuated after accounting for use of adjuvant therapy.
Between 1990-1991 and 2000-2001, the proportion of
patients with tumors with high nuclear grade decreased from
46% to 32% (P  = 0.03) and those with involved surgical
margins dropped from 15% to 0% (P = 0.03).
Conclusions The marked increase in the 1990s in the use of
adjuvant therapy for ductal carcinoma in situ patients treated
with breast-conserving surgery in the community setting only
partially explains the 50% decline in risk of recurrence. Changes
in pathology factors have likely also contributed to this decline.
BCPT: Breast Cancer Prevention Trial; BCS: breast-conserving therapy; BMI: body mass index; CRN: Cancer Research Network; DCIS: ductal car-
cinoma in situ; EORTC: European Organization for Research and Treatment of Cancer; ER: estrogen receptor; FDA: Federal Drug Administration; 
HMO: health maintenance organizations; HPHC: Harvard Pilgrim Health Care; KPNC: Kaiser Permanente of Northern California; KPSC: Kaiser Per-
manente of Southern California; NCCN: National Comprehensive Cancer Network; NSABP: National Surgical Adjuvant Breast and Bowel Project; 
SEER: Surveillance, Epidemiology, and End Results.Breast Cancer Research    Vol 11 No 6    Habel et al.
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Introduction
The diagnosis of ductal carcinoma in situ (DCIS) has
increased several-fold since the early 1980s [1,2], due mainly
to the increase in mammographic screening and the greater
tendency to biopsy radiographically suspicious lesions. Previ-
ously, DCIS constituted 1 to 5% of breast cancer diagnoses
and was usually detected as a palpable mass. DCIS currently
accounts for up to 20% of the breast cancers diagnosed in
screened populations [3] and is frequently microscopic and
asymptomatic [4]. It is estimated that approximately 58,000
new cases of DCIS were diagnosed in the U.S. in 2008 [5].
Before the 1980s, virtually all breast cancer, in situ as well as
invasive, was treated with mastectomy. In the mid-1980s, clin-
ical trials demonstrated that breast-conserving surgery (BCS)
is an appropriate treatment strategy for most early invasive
breast cancer [6,7]. Consequently, use of BCS was also con-
sidered appropriate for most patients with DCIS. Up to 70%
of DCIS patients in the U.S. are currently being treated with
BCS, although use of BCS varies by geographic region and is
highest in the northeast and west [8,9].
Currently recommended breast-conserving regimens for DCIS
include breast-conserving surgery (BCS) alone, BCS plus
radiotherapy, and BCS plus radiotherapy and tamoxifen
[10,11]; however, there is no consensus on which women
should be treated with the different regimens. No other adju-
vant therapies are approved for DCIS, although some, such as
aromatase inhibitors, are being evaluated in clinical trials [12].
Among DCIS patients treated with BCS, use of adjuvant radi-
otherapy has increased substantially over the last two dec-
ades [2,8,9]. More recently, the use of tamoxifen, which was
approved by the U.S. Federal Drug Administration (FDA) as
adjuvant therapy for DCIS in 2000 [13], has also increased in
this population [14]. The extent to which other therapies, such
as aromatase inhibitors, are being used off-label is unclear.
Cancers considered to be recurrent disease by a clinician are
not captured well by most cancer registries, such as the
National Cancer Institutes' Surveillance, Epidemiology, and
End Results (SEER) program of registries, which only cap-
tures new primary cancers. Consequently, there are few pop-
ulation-based data available on risk of local recurrence
following BCS for DCIS. Data from randomized trials indicate
that treatment with adjuvant radiotherapy decreases local
recurrences by about 50% [15-17]. Although clinical trial data
have been somewhat conflicting [18,19], it appears that add-
ing tamoxifen to BCS plus radiotherapy may decrease local
recurrences by another 50% [18]. Overall, the addition of
these two adjuvant therapies to BCS alone appears to reduce
the five-year local recurrence rate (combination of DCIS and
invasive disease) from 20% to approximately 8% [15,19].
However, we do not know if results of randomized clinical trials
of treatment effects are generalizable to the community set-
ting. To our knowledge, data are currently unavailable on
whether rates of local recurrence in the community setting
have changed as the use of these adjuvant therapies for DCIS
has increased.
The aims of this study were to determine: 1) trends in adjuvant
treatment among DCIS patients diagnosed between 1990
and 2001 and treated with BCS in three community-based
health care plans, and 2) five-year risk of local recurrence or
any second breast cancer event among those diagnosed
between 1990 and 1999. We also examined the extent to
which treatment with radiotherapy and tamoxifen could explain
observed time trends in risk of recurrence. Finally, we deter-
mined whether there have been changes in histopathologic
factors that could have contributed to observed trends.
Materials and methods
The study was conducted under the auspices of the National
Cancer Institute-funded Cancer Research Network (CRN), a
consortium of 14 health maintenance organizations (HMOs)
with more than 12 million enrollees. The overall goal of the
CRN is to increase the effectiveness of preventive, curative,
and supportive interventions for major cancers through a pro-
gram of collaborative research, and to determine the effective-
ness of cancer control interventions that span the natural
history of major cancers among diverse populations and health
systems.
Study population
We identified all patients diagnosed with a first primary unilat-
eral DCIS between 1990 and 2001 and treated with BCS at
three HMOs participating in the CRN: Kaiser Permanente of
Northern California (KPNC), Kaiser Permanente of Southern
California (KPSC), and Harvard Pilgrim Health Care (HPHC).
Patients were eligible if they were less than age 85 years at
diagnosis and had no prior invasive cancer (breast or other
site). Patients were excluded if breast cancer (DCIS or inva-
sive disease) was diagnosed in the contralateral breast at the
time of the index DCIS diagnosis or if they had a mastectomy
within six months of their index DCIS. Patients were also
excluded if medical care (treatment or follow-up) for their DCIS
was obtained from providers outside of the three health plans.
Data sources
Cancer registries were used to identify patients with an initial
diagnosis of DCIS at KPNC and KPSC. These registries pro-
vide data on new primary cancers to the SEER program and
include information on birth date, race/ethnicity, prior cancer
diagnoses, laterality of the index DCIS, type of surgical treat-
ment, treatment with radiotherapy, and treatment with hormo-
nal therapy. At HPHC, electronic medical records and claims
codes were used to identify DCIS diagnoses and surgical
treatment.Available online http://breast-cancer-research.com/content/11/6/R85
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At each of the three health plans, medical records of poten-
tially eligible patients were reviewed to confirm the initial diag-
nosis, treatment, and laterality of the index DCIS and to obtain
information on subsequent breast cancer events. Information
was also collected on history of breast cancer, surveillance
mammography, and on all subsequent breast biopsies. In addi-
tion, data were abstracted on several patient and clinical fac-
tors at the time of their index DCIS (for example, method of
detection, family history of breast cancer in first degree rela-
tive, height, weight).
To explore whether several pathologic features considered to
be risk factors for recurrence after DCIS [20-26] may have
changed over time and contributed to changes in risk of recur-
rence, we examined their distributions by diagnosis year
among patients included in a case-control study nested within
this same DCIS cohort. This case-control study included all
recurrences (cases). At each case's recurrence, up to two
patients (controls) were randomly selected from cohort mem-
bers still under follow-up and without a recurrence (that is, inci-
dence density sampling [27]). Controls were individually
matched to their case on health plan, age at diagnosis (<45,
45 to 54, 55 to 64, 65 to 84 years), and calendar year of diag-
nosis (1990-1991, 1992-1993, 1994-1995, 1996-1997,
1998-1999, and 2000-2001).
Diagnostic slides were available on 297 cases and 496 con-
trols, and a standardized central histopathology review was
conducted by expert DCIS pathologists (authors SJS, LCC)
that included confirmation of the initial DCIS diagnosis (cases
= 245, controls = 416) and the assessment of multiple fea-
tures including evaluation of surgical margins, and among
those with uninvolved margins, width of margin. A margin was
scored as involved if there was DCIS at the inked tissue edge
and as close if there was DCIS within 1 mm of the inked mar-
gin. The extent of margin involvement was recorded as a linear
value, but also as the number of low power microscopic fields
of DCIS at or close to the inked margin. Other features
included tumor size, predominant nuclear grade, necrosis
(comedo or punctate) and primary architectural pattern
(comedo, solid, papillary, micropapillary, cribriform or clinging),
among others.
Tumor blocks were retrieved on 210 cases (89%) and 364
controls (88%) and sent to PhenoPath Laboratories (Seattle,
WA) for estrogen receptor (ER) immunostaining (rabbit mon-
oclonal (clone SP1), Lab Vision) and scoring. Immunostains
were performed on four to five-micron sections cut from a sin-
gle paraffin block and appropriate positive and negative con-
trols were included in each staining run. The scoring was
conducted by visually estimating the percentage of ER-posi-
tive nuclei in the tumor population. Those with <1% staining
were scored as 0 (negative); the positives were scored as 1 to
25% = 1+, 25 to 75% = 2+, >75% = 3+.
Endpoints
Local recurrence was our primary endpoint of interest and was
defined as DCIS or invasive breast cancer in the involved or
ipsilateral breast at least six months after the index diagnosis.
Women with a local recurrence included those with an ipsilat-
eral breast tumor only as well as those who had ipsilateral dis-
ease with regional or distant involvement. Secondary analyses
were conducted for: 1) any second breast cancer event, which
included local recurrences, contralateral breast cancers and
regional or distant breast metastases (with or without local
involvement) and 2) contralateral disease only, since tamoxifen
also has been shown to reduce the risk of these endpoints
[18].
DCIS or invasive disease identified during the first six months
after the index DCIS was considered part of the initial disease.
Therefore, women with invasive breast cancers identified dur-
ing this period were excluded from the cohort as they were
considered to have invasive disease, and not pure DCIS, at
presentation.
Statistical analyses
Follow-up began at six months after diagnosis of DCIS and
ended at date of recurrence, prophylactic mastectomy of the
ipsilateral breast, contralateral breast cancer, non-breast inva-
sive cancer, death, or last chart note, whichever came first. All
endpoints were defined with respect to the first event follow-
ing DCIS diagnosis and did not include breast cancer events
that occurred after the first subsequent cancer. Five-year risk
estimates (any local recurrence, local invasive recurrence, any
second breast cancer, any second invasive breast cancer,
contralateral breast cancer) were generated [28,29], stratified
by diagnosis year and, for some analyses, by treatment. These
analyses were restricted to diagnosis years 1990 to 1999 so
that patients would have the opportunity for five years of fol-
low-up (most follow-up ended in 2004). In addition, Cox
regression modeling was used to estimate relative risks for
recurrence associated with diagnosis year (1990 to 1999),
both with and without adjustment for treatment with radiother-
apy and tamoxifen [30]. We also examined potential confound-
ing by age, race, family history of breast cancer, body mass
index (BMI), method of detection of the initial DCIS, and re-
excision or post-surgical mammogram in the three months
after initial biopsy with DCIS. Time since diagnosis of the index
DCIS was the time scale in these Cox models. These Cox
model analyses censored follow-up time at five years to be
consistent with the risk estimates. Results for analyses with
and without censoring at five years were similar, and so we
have only presented the censored results. We tested the valid-
ity of the proportional hazards assumption by adding an inter-
action term between diagnosis year and time, and there was
no evidence of non-proportionality.
It is important to note that because the standardized pathology
review was conducted only on cases and controls andBreast Cancer Research    Vol 11 No 6    Habel et al.
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because cases and controls were matched on diagnosis year,
it was not possible to adjust diagnosis year estimates for path-
ologic variables. F-tests were performed to examine changes
over time.
Institutional Review Board approval
The study was approved by the Kaiser Permanente Inter-
regional Institutional Review Board (for KPNC and KPSC) and
by the Institutional Review Boards at Harvard Pilgrim Health
Care and Beth Israel Deaconess Medical Center.
Results
Of the 3,668 patients identified as potentially eligible by our
cancer registries or electronic medical records, there were
520 patients who were determined by chart review to be inel-
igible for one or more of the following reasons: miscoded as
having DCIS in the tumor registry or diagnosed with invasive
breast cancer within six months of index DCIS (n = 97), syn-
chronous cancer in the uninvolved or contralateral breast (n =
29), prior breast cancer (n = 91), prior invasive cancer at
another site (n = 125), 85 years of age or older at diagnosis (n
= 15) or had less than six months of follow-up (mastectomy
within six months (n = 96), death within six months (n = 6), or
not a member at diagnosis or left the health plan within six
months (n = 92)). The eligibility of 82 patients could not be
determined because of incomplete or unavailable medical
records and they were considered lost to the study. Also, 29
did not have complete information on adjuvant therapy. Of the
3,037 women determined to be eligible by chart review, 42
had no pathology report confirming breast-conserving surgery,
leaving 2,995 patients available for this study.
Characteristics of the final cohort
Of the 2,995 eligible DCIS patients, 325 (10.9%) had a recur-
rence as a first cancer event during a median follow-up of 4.8
years (range 0.5 to 15.7 years). Of these recurrences, 294
were confined to the ipsilateral breast, and 31 had an ipsilat-
eral breast tumor plus regional or distant involvement. An addi-
tional nine patients had regional/distant disease without
evidence of an ipsilateral tumor. Another 129 DCIS patients
had a subsequent cancer in the contralateral breast as a first
event during follow-up. There were 18 women whose follow-
up time was censored at the time of prophylactic mastectomy
of the ipsilateral breast, 133 at diagnosis of non-breast inva-
sive cancer, 69 at death, and 2,312 at last chart note.
The number of patients with an index DCIS diagnosis in 2000-
2001 was almost triple that in 1990-1991 (Table 1), reflecting
the increasing diagnosis rates as well as the increasing use of
BCS over time. The majority of DCIS patients were white, but
approximately a third were minorities; 25% were younger than
age 50 years, and 19% were age 70 years or older at the index
DCIS diagnosis. Approximately 43% of patients were treated
with BCS alone, 42% with BCS plus radiotherapy, 11% with
BCS plus radiotherapy and tamoxifen, and less than 5% with
BCS plus tamoxifen.
Treatment trends
Among DCIS patients treated with BCS, the use of adjuvant
radiotherapy increased from 25.8% for patients diagnosed in
1990-1991 to 61.3% for those diagnosed in 2000-2001 (Fig-
ure 1). Treatment with adjuvant tamoxifen increased from
2.3% to 34.4% during this same period.
Risk of local recurrence and other breast cancer events 
at five years
Of the 325 local recurrences, 245 occurred within the first five
years. Within five years, there were a total of 358 patients with
any second breast cancer (245 with local recurrence, 28 with
regional or distant recurrences with or without local involve-
ment and 85 with contralateral cancer).
The five-year risk of a local recurrence (DCIS or invasive)
decreased from 14.3% (95% CI 9.8 to 18.7) for patients diag-
nosed in 1990-1991 to 7.7% (95% CI 5.5 to 9.9) for patients
diagnosed in 1998-1999 (Figure 2). The risk of an invasive
local recurrence decreased from 7.0% (95% CI 3.8 to 10.3)
in 1990-1991 to 3.1% (95% CI 1.7 to 4.6) in 1998-1999.
Among patients treated with BCS alone (no radiotherapy or
tamoxifen), the five-year risk of local recurrence was 17.3%
(95% CI 11.7 to 23.0) in 1990-1991 and 13.3% (95% CI 8.4
to 18.2) in 1998-1999; it was 8.5% (95% CI 1.4 to 15.7) and
6.1% (95% CI 3.2 to 8.9), respectively, for those treated with
BCS plus radiotherapy. There were too few patients treated
with tamoxifen in the early 1990s for reliable risk estimates
across calendar years.
The five-year risk of any second breast cancer event (ipsilat-
eral, contralateral or regional/distant disease) decreased from
18.5% (95% CI 13.6 to 23.5) for patients diagnosed in 1990-
1991 to 11.0% (95% CI 8.4 to 13.6) for patients diagnosed
in 1998-1999 (Figure 3). The risk of any second invasive
breast cancer decreased from 9.2% (95% CI 5.5 to 12.9) in
1990-1991 to 5.5% (95% CI 3.5 to 7.4) in 1998-1999.
Among patients treated with BCS alone (no radiotherapy or
tamoxifen), the five-year risk of any second breast cancer was
20.8% (95% CI 14.7 to 26.9) in 1990-1991 and 15.2% (95%
CI 10.0 to - 20.4) in 1998-1999; it was 15.4% (95% CI 6.1 to
24.7) and 11.2% (95% CI 7.4 to 15.0), respectively, for those
treated with BCS plus radiotherapy.
The five-year risk of any contralateral disease slightly
decreased from 3.8% (95% CI 1.4 to 6.2) for patients diag-
nosed in 1990-1991 to 3.2% (95% CI 1.7 to 4.7) for patients
diagnosed in 1998-1999. Among patients treated with BCS
alone (no radiotherapy or tamoxifen), the five-year risk of any
contralateral disease was 2.9% (95% CI 0.4 to 5.4) in 1990-Available online http://breast-cancer-research.com/content/11/6/R85
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Table 1
Selected characteristics of DCISa study cohort
Characteristics Full cohort
(Number)
% Recurrences
(Number)
%
Total 2995 100.0 325 100.0
Diagnosis year
1990-1991 256 8.6 54 16.6
1992-1993 354 11.8 50 15.4
1994-1995 444 14.8 76 23.4
1996-1997 558 18.6 81 24.9
1998-1999 663 22.1 47 14.5
2000-2001 720 24.0 17 5.2
Age at diagnosis (years)
<50 767 25.6 103 31.7
50-59 853 28.5 94 28.9
60-69 800 26.7 86 26.5
70+ 575 19.2 42 12.9
Race
Asian 360 12.0 29 8.9
Black 289 9.6 47 14.5
Hispanic 257 8.6 28 8.6
Other 8 0.3 0 0.0
White 2045 68.3 220 67.7
Unknown 36 1.2 1 0.3
Adjuvant therapy
None (BCSb only) 1275 42.6 223 68.6
Radiotherapy (no Tamoxifen) 1257 42.0 95 29.2
Tamoxifen (no Radiotherapy) 132 4.4 2 0.6
Radiotherapy+Tamoxifen 331 11.0 5 1.5
a Ductal carcinoma in situ
b Breast-conserving surgeryBreast Cancer Research    Vol 11 No 6    Habel et al.
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1991 and 1.9% (95% CI 0.04 to 3.8) in 1998-1999; it was
6.9% (95% CI 0.4 to 13.4) and 4.8% (95% CI 2.2 to 7.4),
respectively, for those treated with BCS plus radiotherapy.
In Cox models accounting for time since diagnosis, the asso-
ciation between diagnosis year and risk of recurrence was
modestly attenuated after adjustment for radiotherapy and
tamoxifen (Table 2). Additional adjustment for age (using five-
year age categories), race, family history of breast cancer,
body mass index (BMI), method of detection of the initial
DCIS, re-excision, or post-surgical mammogram in the three
months after initial biopsy with DCIS did not materially change
the relative risk estimates (not shown).
Trends in pathologic factors
Among the subgroup of DCIS patients included in the case-
control study, there was very little change in tumor size across
the diagnosis years 1990 to 2001. For example, the mean
tumor size in calendar years 1990-1991, 1995-1996, and
2000-2001 was 11.5 mm (range 0.5 to 50 mm), 11.0 mm
(range 1.0 to 37 mm), and 9.6 mm (range 0.5 to 34 mm) (P =
0.44), respectively. In contrast, the proportion of patients with
high nuclear grade tumors decreased; in calendar years 1990-
1991, 1995-1996, and 2000-2001, it was 46%, 28%, and
32%, respectively (P = 0.03). In addition, patients diagnosed
in the later calendar years were less likely to have involved sur-
gical margins. The proportion with involved surgical margins in
calendar years 1990-1991, 1995-1996, and 2000-2001
were 15%, 10%, and 0%, respectively (P = 0.03). However,
among those with clear surgical margins and with a known dis-
tance between the margin and the tumor, the proportion with
a surgical margin of 10 mm or more did not appear to increase
over time. For example, the proportion with a surgical margin
of 10 mm or more in calendar years 1990-1991, 1995-1996,
and 2000-2001 was 39%, 28%, and 30%, respectively (P =
0.37). The proportion of patients with comedo necrosis
decreased only slightly; in calendar years 1990-1991, 1995-
1996, and 2000-2001, it was 65%, 52%, and 55%, respec-
tively (P  = 0.14). The proportion of ER-negative tumors
decreased somewhat; in calendar years 1990-1991, 1995-
1996, and 2000-2001, it was 19%, 13%, and 11%, respec-
tively (P = 0.44).
Figure 1
Adjuvant treatment by diagnosis year Adjuvant treatment by diagnosis year. The white bars indicate the per-
cent of women treated with radiotherapy (with or without tamoxifen); 
the black bars indicate the percent of women treated with tamoxifen 
(with or without radiotherapy).
Figure 2
Five-year risk of local recurrence by diagnosis year Five-year risk of local recurrence by diagnosis year. The white bars indi-
cate the risk of any local recurrence; the grey bars indicate the risk of 
an invasive local recurrence. The length of the vertical line through the 
bar indicates the 95% confidence interval (CI).
Figure 3
Five-year risk of any second breast cancer by diagnosis year Five-year risk of any second breast cancer by diagnosis year. The white 
bars indicate the risk of any second breast cancer; the grey bars indi-
cate the risk of an invasive second breast cancer. The length of the ver-
tical line through the bar indicates the 95% confidence interval (CI).Available online http://breast-cancer-research.com/content/11/6/R85
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Table 2
Relative risks of local recurrence and of any second breast cancer at five years associated with diagnosis year
Local recurrence Any second breast cancer
RRa 95% CIb RRa 95% CIb
Univariate models
Diagnosis year
1990-1991 1.0 (reference) 1.0 (reference)
1992-1993 0.7 0.5-1.0 0.8 0.6-1.1
1994-1995 0.8 0.6-1.2 0.9 0.6-1.2
1996-1997 0.7 0.5-1.0 0.7 0.5-0.9
1998-1999 0.4 0.3-0.6 0.4 0.3-0.6
P for trend < 0.0001 P for trend < 0.0001
Adjuvant therapy
None (BCSc only) 1.0 (reference) 1.0 (reference)
Radiotherapy 0.4 0.3-0.5 0.6 0.5-0.7
Tamoxifen 0.1 0.04-0.6 0.2 0.1-0.6
Radiotherapy+Tamoxifen 0.1 0.05-0.4 0.3 0.1-0.5
Multivariable model (with treatment variables)
Diagnosis yeard
1990-1991 1.0 (reference) 1.0 (reference)
1992-1993 0.8 0.6-1.2 0.9 0.7-1.3
1994-1995 1.0 0.7-1.4 1.0 0.7-1.3
1996-1997 0.8 0.6-1.2 0.8 0.6-1.1
1998-1999 0.6 0.4-0.8 0.6 0.4-0.8
P for trend = 0.008 P for trend = 0.0002
Adjuvant therapy
None (BCSc only) 1.0 (reference) 1.0 (reference)
Radiotherapy 0.4 0.3-0.6 0.6 0.5-0.8
Tamoxifen 0.2 0.04-0.7 0.2 0.1-0.7
Radiotherapy+Tamoxifen 0.2 0.06-0.4 0.3 0.2-0.6
a Relative Risk
b Confidence Interval
c Breast-conserving surgery
d Model adjusted for adjuvant therapy (none, radiotherapy, tamoxifen)Breast Cancer Research    Vol 11 No 6    Habel et al.
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Discussion
To our knowledge, this is the first study to provide information
on changing risk of recurrence among DCIS patients treated
with BCS in the community setting. Our findings suggest that
DCIS patients diagnosed in the late 1990s had approximately
half the risk of a recurrence at five years compared to patients
diagnosed in the early 1990s. Furthermore, this was observed
for recurrences that included both DCIS and invasive disease
and when recurrences were restricted to invasive disease. The
decline appeared to be only partially due to an increase in use
of adjuvant radiotherapy and tamoxifen. Changes in pathologic
practice during this period particularly with regard to margin
evaluation also likely contributed to this decline.
Some limitations should be considered when interpreting our
findings. While our study was drawn from the memberships of
three large and diverse health plans, the results may not be
generalizable to all geographic regions or community health
care settings. However, the marked increases that we
observed in adjuvant treatment with radiotherapy and
tamoxifen over the study period are generally similar to those
reported for DCIS patients in the overall U.S. population,
based on the SEER Program Cancer Registries [2,8]. Con-
versely, treatment with tamoxifen in our health plans was
somewhat lower than that reported for patients treated in
National Comprehensive Cancer Network (NCCN) centers
(for example, 34% in our health plans vs. 40 to 50% of NCCN
patients in calendar years 2000-2001 [14]).
We did not have information on estrogen receptor (ER) status,
a current indicator for treatment with tamoxifen [10], on the full
patient cohort. We also did not have information on the full
patient cohort on other pathologic features that may be asso-
ciated with an increased risk of recurrence, such as large
tumor size [20], high nuclear grade [21-24], involved or nar-
rowly free surgical margins [21,25,26,31,32], and comedo
necrosis [33]. However, pathology data from a central stand-
ardized review were available on a large subset of the cohort.
While we were unable to adjust for pathology factors because
cases and controls were matched on calendar year, our data
indicated that there was little change in the distribution of
tumor size over the calendar years of our study. It did appear
that patients diagnosed and treated with BCS in the later cal-
endar years were less likely to have high nuclear grade tumors
and more likely to have clear surgical margins, although the
proportion with wide margins did not seem to increase over
time. They were also slightly less likely to have tumors with
comedo necrosis or tumors that were ER-negative, although
these changes were not statistically significant. While data are
limited on potential changes over time in specific characteris-
tics of DCIS diagnosed in the community setting, a similar
slight decrease in the incidence of comedo DCIS has been
observed in the national SEER data on DCIS [34]. The case-
control design for our pathology data, with matching on diag-
nosis year, prevented us from directly examining the associa-
tion between changes in histopathology and risk of recurrence
over time. Nonetheless, our observation that several higher risk
pathologic factors (such as high nuclear grade, comedo
necrosis, involved margins) have decreased over time does
suggest that changes in the proportion of patients with these
factors may have at least in part, contributed to our observed
decline in risk of recurrence among DCIS patients diagnosed
and treated in the 1990s.
Published results are available from five prospective, rand-
omized clinical trials of BCS treatment for DCIS [15,17-
19,35,36]. In NSABP B-17, the five-year risk of ipsilateral
breast cancer was 13.4% in women treated with lumpectomy
plus radiotherapy, and 20.9% in women treated by lumpec-
tomy alone [15]. Similar results were found in the EORTC
10853 and SweDCIS studies [16,17]. Women in the radio-
therapy plus tamoxifen arm of the NSABP B-24 trial had fewer
breast cancer events at five years than did those on radiother-
apy plus placebo (8.2% vs. 13.4%, P = 0.0009) [15]. How-
ever, the UK/ANZ trial of BCS with or without radiotherapy and
with or without tamoxifen found a reduction in ipsilateral DCIS,
but not ipsilateral invasive disease, associated with tamoxifen
therapy [19].
Our risk estimates for patients diagnosed in the early 1990s
are fairly consistent with those reported in these clinical trials
and from other population-based studies of DCIS [22,37],
suggesting that, contrary to concerns [38], results from clini-
cal trials of DCIS treatment appear to be generalizable to com-
munity practice. Our results are also consistent with
observational studies that indicate that the use of these adju-
vant therapies has increased substantially among DCIS
patients treated with BCS [2,8,14]. As expected, we observed
a substantial increase in use of adjuvant radiotherapy in 1992/
1993, about the time when the first results of the NSABP B-
17 trial were presented and published showing a 50% reduc-
tion in recurrence associated with use of radiotherapy among
patients treated with lumpectomy [39]. In 1992 and 1993, we
observed a slight increase in the use of tamoxifen, which was
coincident with the middle of the accrual period for the
NSABP B-24 trial of BCS and radiotherapy with or without
adjuvant tamoxifen. The decrease in tamoxifen use in1994 may
have been in response to reports that tamoxifen increases the
risk of endometrial cancer [40]. We observed another
increase in tamoxifen use in 1998 and 1999 when the first
NSABP B-24 results showing a 50% reduction in recurrences
were published [39]. Tamoxifen use for DCIS during the mid-
to-late 1990s also may have been influenced by the Breast
Cancer Prevention Trial (BCPT), which was designed to exam-
ine whether tamoxifen could prevent the development of
breast cancer [41]. Women at high risk, but without a personal
history of breast cancer (DCIS or invasive disease), were
enrolled in the BCPT between 1992 and 1997.Available online http://breast-cancer-research.com/content/11/6/R85
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While the age-adjusted incidence of a diagnosis of DCIS has
increased during the 1990s [8], our results suggest that
increasing use of adjuvant radiotherapy and tamoxifen during
this same period contributed to a substantial decrease in the
five-year risk of recurrence among DCIS patients treated with
BCS in the community setting. Nonetheless, it should be
noted that neither adjuvant radiotherapy nor radiotherapy plus
tamoxifen have been shown to have a survival benefit and
there is currently no consensus that all DCIS patients treated
with BCS should receive adjuvant radiotherapy and tamoxifen
[10,11]. Additional research is needed to confirm our findings,
to examine whether the decline in risk of recurrence has con-
tinued for later diagnosis years, and to further examine the
extent to which an increase in the proportion of patients with
clear surgical margins or low or intermediate nuclear grade, or
other factors, may also contribute to our observed decrease in
risk of recurrence for DCIS patients treated with BCS.
Conclusions
The marked increase in the 1990s in the use of radiotherapy
and/or tamoxifen for DCIS patients treated with BCS sug-
gests dissemination of findings from randomized trials into
community practice. In our settings, treatment of DCIS in the
late 1990s was associated with a five-year risk of recurrence
of only 8% when BCS was used. If use of adjuvant radiother-
apy and tamoxifen increased further after the late 1990s and
early 2000s, as is likely given that adjuvant tamoxifen was only
approved for DCIS patients in 2000, the five-year risk of recur-
rence may be even lower for DCIS patients diagnosed and
treated more recently in the community setting. Further
improvements in complete surgical excision and histologic
assessment of DCIS lesions may also help to decrease recur-
rence rates.
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